Document:

Instrument of Resignation, Appointment and Acceptance

 Exhibit 4.3 
 INSTRUMENT OF RESIGNATION, APPOINTMENT AND ACCEPTANCE, dated as of January 19, 2012 (this “Instrument”), among TRAVELPORT LLC, a Delaware limited liability company (the
“Issuer”), COMPUTERSHARE TRUST COMPANY, N.A., a federally chartered trust company duly organized and existing under the laws of the United States of America, as successor Trustee (the “Successor
Trustee”), and THE BANK OF NOVA SCOTIA TRUST COMPANY OF NEW YORK, a trust company organized and existing under the laws of the State of New York (the “Resigning Trustee”). 

RECITALS 
 WHEREAS, the Issuer, the Resigning Trustee, and certain Guarantors are parties to the Indenture, dated as of August 23, 2006, as supplemented by, Supplemental Indenture No. 1, dated as of
January 11, 2007, between Warpspeed Sub Inc. and the Resigning Trustee, and as further supplemented by, Supplemental Indenture No. 2, dated as of March 13, 2007, among the Issuer, TDS Investor (Luxembourg) S.à.r.l., Travelport
Inc., Orbitz Worldwide, Inc., Travelport Holdings, Inc. and the Resigning Trustee, and as further supplemented by, Supplemental Indenture No. 3, among the Issuer, Worldspan Technologies Inc., Worldspan BBN Holdings, LLC, Worldspan Digital
Holdings, LLC, Worldspan !Jet Holdings, LLC, Worldspan OpenTable Holdings, LLC, Worldspan S.A. Holdings II, L.L.C., Worldspan StoreMaker Holdings, LLC, Worldspan South American Holdings LLC, Worldspan Viator Holdings, LLC, Worldspan XOL LLC, WS
Financing Corp., Worldspan, L.P. and WS Holdings LLC, and Resigning Trustee (collectively, the “Indenture”), pursuant to which (i) $300,000,000 in original aggregate principal amount of the Issuer’s 117/8% Dollar Senior Subordinated Notes due 2016, and
(ii) €160,000,000 in original aggregate principal amount of the Issuer’s 107/8% Euro Senior Subordinated Notes due 2016 (together, the “Notes”) were issued. 
 WHEREAS, the Resigning Trustee wishes to resign as Trustee under the Indenture; the Issuer wishes to appoint the Successor Trustee to succeed the Resigning Trustee as Trustee under the Indenture; and the
Successor Trustee wishes to accept appointment as Trustee under the Indenture. 
 NOW, THEREFORE, in consideration of the mutual
covenants and promises herein, the receipt and sufficiency of which are hereby acknowledged, the Issuer, the Resigning Trustee and the Successor Trustee agree as follows: 
 ARTICLE ONE 
 THE RESIGNING TRUSTEE 

Section 101. Pursuant to Section 7.08 of the Indenture, the Resigning Trustee resigns as Trustee, Registrar and Paying
Agent under the Indenture. 
 Section 102. The Resigning Trustee hereby represents and warrants to the Successor
Trustee that: 
 (a) No covenant or condition contained in the Indenture has been waived by the Resigning Trustee
in violation of the Indenture. 

 (b) There is no action, suit or proceeding pending or, to the best of the
knowledge of Responsible Officers of the Resigning Trustee assigned to its corporate trust department, threatened in writing against the Resigning Trustee before any court or governmental authority related to the Indenture, except for the following:

  

	 	(i)	that certain civil action styled as Travelport Limited, Travelport, LLC and Travelport Inc. v. The Bank of Nova Scotia Trust Company of New York, as Trustee, Case
No. 11-CV-7704 (S.D.N.Y. 2011) (the “Litigation”). 

 (c) This Instrument has been
duly authorized, executed and delivered on behalf of the Resigning Trustee. 
 (d) As of the date hereof, the
Resigning Trustee holds no property or money under the Indenture. 
 (e) The current
principal amount of indebtedness evidenced by the 117/8%
Dollar Senior Subordinated Notes due 2016 is $247,200,000. 
 (f) The current principal
amount of indebtedness evidenced by the 107/8% Euro Senior
Subordinated Notes due 2016 is €139,750,000. 
 (g) All the interest on each of the Notes has been paid
through September 1, 2011. 
 (h) To the best knowledge of Responsible Officers of the Resigning Trustee
assigned to its corporate trust department, the Resigning Trustee has lawfully discharged its duties as Trustee under the Indenture. 
 Section 103. Subject to the terms and limitations in this Instrument, the Resigning Trustee hereby assigns, transfers, delivers and confirms to the Successor Trustee all right, title and
interest of the Resigning Trustee in its capacity as Trustee, Registrar and Paying Agent under the Indenture in and to the trust under the Indenture, including all the rights, powers and duties of the Resigning Trustee under the Indenture (except
for the Resigning Trustee’s fees and expenses incurred prior to the date hereof and in connection with the execution and delivery of this Instrument, as addressed in Section 303 below and the Resigning Trustee’s other rights under
Section 7.07 of the Indenture). The Resigning Trustee shall execute and deliver such further instruments and shall do such other things as the Successor Trustee may reasonably require so as to more fully and certainly vest and confirm in the
Successor Trustee all the rights, powers and duties hereby assigned, transferred, delivered and confirmed to the Successor Trustee. 
 Section 104. As of or promptly after the effective date of this Instrument, the Resigning Trustee shall deliver to the Successor Trustee the items listed on Exhibit A annexed hereto.

  
 2 

 ARTICLE TWO 
 THE ISSUER 
 Section 201. The Issuer hereby certifies that it is, and
the officers of such Issuer who have executed this Instrument are, duly authorized to: (a) accept the Resigning Trustee’s resignation as Trustee, Registrar and Paying Agent under the Indenture, and (b) appoint the Successor Trustee as
Trustee, Registrar and Paying Agent under the Indenture. 
 Section 202. The Issuer hereby accepts the resignation
of the Resigning Trustee as Trustee, Registrar and Paying Agent under the Indenture. Pursuant to the applicable provisions of the Indenture, the Issuer hereby appoints the Successor Trustee as Trustee, Registrar and Paying Agent under the Indenture
and confirms to the Successor Trustee all the rights, powers and duties of the Resigning Trustee under the Indenture (except as set forth in Section 103 hereof). The Issuer shall execute and deliver such further instruments and shall do such
other things as the Successor Trustee may reasonably require so as to more fully and certainly vest in and confirm to the Successor Trustee all the rights, powers, and duties hereby assigned, transferred, delivered and confirmed to the Successor
Trustee. 
 Section 203. The Issuer hereby represents and warrants to the Resigning Trustee and the Successor
Trustee that: 
 (a) Travelport LLC is a Delaware limited liability company. 

(b) The Indenture was validly and lawfully executed and delivered by the Issuer and is in full force and effect.

 (c) The Indenture and the Notes are binding obligations of the Issuer as set forth in the Indenture.

 (d) This Instrument has been duly authorized, executed and delivered on behalf of the Issuer and constitutes a
valid, legal and binding obligation of the Issuer. 
 (e) The current principal amount of
indebtedness evidenced by the 117/8% Dollar Senior
Subordinated Notes due 2016 is $247,200,000 and all interest on such notes has been paid through September 1, 2011. 
 (f) The current principal amount of indebtedness evidenced by the
107/8% Euro Senior Subordinated Notes due 2016 is
€139,750,000 and all interest on such notes has been paid through September 1, 2011. 
 Section 204. The
Issuer (i) acknowledges that the Successor Trustee, concurrently with the execution of this Instrument, also is replacing the Resigning Trustee as trustee under the indentures listed on Schedule 1 annexed hereto (the “Other
Indentures”) pursuant to which the Issuer (or its predecessors) and/or Travelport Inc. issued senior debt securities and (ii) agrees that it will not argue or contend that the Successor Trustee’s acceptance of a successor
trusteeship under such Other Indentures is an acknowledgement or admission that no default or Event of Default exists under the Indenture on the effective date of this Instrument. 

  
 3 

 ARTICLE THREE 
 THE SUCCESSOR TRUSTEE 
 Section 301. The Successor Trustee hereby
represents and warrants to the Resigning Trustee and the Issuer that: 
 (a) The Successor Trustee is eligible
and qualified under the Indenture and under the Trust Indenture Act of 1939, as amended, to act as Trustee under the Indenture. 
 (b) The Successor Trustee is a federally chartered trust company duly organized and existing under the laws of the United States of America and is authorized under such laws to exercise trust powers and
is subject to supervision or examination by United States federal authority. 
 (c) This Instrument has been duly
authorized, executed and delivered on behalf of the Successor Trustee and constitutes a valid, legal and binding obligation of the Successor Trustee. 
 Section 302. As of or promptly after the effective date of this Instrument, the Successor Trustee shall cause a notice, substantially in the form of Exhibit B annexed hereto, to be sent
to each Holder of the Notes in accordance with the Indenture. 
 Section 303. Notwithstanding this Instrument and
the resignation of the Resigning Trustee, the Issuer shall reimburse the Resigning Trustee for the Resigning Trustee’s reasonable fees and expenses, and the Resigning Trustee shall retain all rights and entitlements relating to its service as
Trustee, Registrar, and Paying Agent under the Indenture arising or accruing in connection with its service thereunder and arising or accruing in connection with the execution and delivery of this Instrument, including without limitation, all rights
and entitlements to indemnification, including with respect to the Litigation, and to the payment of its fees and reimbursement of its expenses, regardless of when such amounts become payable or are paid. In the event and to the extent the Successor
Trustee shall exercise any lien upon the distributions to Holders of the Notes or otherwise becomes entitled to receive payment of funds subject to Section 6.13 of the Indenture, or payment otherwise of any fees and expenses as Trustee under
the Indenture for any reason at a time when the Resigning Trustee has not been fully paid, it shall do so for both its own fees and expenses and the outstanding fees and expenses of the Resigning Trustee, incurred in connection with its duties under
the Indenture prior to the effective date of this Instrument, the execution and delivery of this Instrument and any subsequent transitional services requested by the Successor Trustee from the Resigning Trustee after the effective date of this
Instrument. The Successor Trustee, after payment of its own fees and expenses and those of its counsel, shall promptly pay over a pro rata portion of any and all such proceeds to the Resigning Trustee when and as received. To the extent the
Resigning Trustee receives funds from the Issuer, other than for payment of the Resigning Trustee’s fees and expenses or other amounts that the Resigning Trustee is otherwise entitled to receive, it agrees to hold those funds as agent for the
Successor Trustee and promptly pay over such funds to, or as directed by, the Successor Trustee. 

  
 4 

 ARTICLE FOUR 
 MISCELLANEOUS 
 Section 401. Except as otherwise expressly provided or
unless the context otherwise requires, all capitalized terms used herein which are defined in the Indenture shall have the meanings assigned to them in the Indenture. 
 Section 402. This Instrument and the resignation, appointment and acceptance effected hereby shall be effective as of the close of business on the date first above written, upon the execution
and delivery hereof by each of the parties hereto; provided, however, that the resignation of the Resigning Trustee as Registrar and Paying Agent and the appointment of the Successor Trustee as Registrar and Paying Agent shall be
effective as of the close of business ten (10) business days after the date first written above. 

Section 403. Notwithstanding the resignation of the Resigning Trustee effected hereby or any other provisions hereof, the
Issuer and the Guarantors shall remain obligated under Section 7.07 of the Indenture to compensate, reimburse and indemnify the Resigning Trustee in connection with its service under the Indenture as Trustee, Registrar, and Paying Agent to the
same extent as if no resignation shall have occurred, including with respect to reasonable fees and expenses related to the Litigation incurred by the Resigning Trustee. The Issuer also acknowledges and reaffirms its obligations to the Successor
Trustee as set forth in Section 7.07 of the Indenture, including its obligation to pay the reasonable fees and expenses (including the reasonable fees and expenses of counsel) incurred by the Successor Trustee in the Litigation, which
obligations shall survive the execution hereof. For the avoidance of doubt, for priority purposes, any fee and/or expense claim arising against the Issuer on account of this Instrument shall be treated as a claim arising out of the Indenture and
shall be afforded the same priority against the Issuer as any fee or expense claim arising out the Indenture. 

Section 404. The Resigning Trustee and the Issuer acknowledge and agree that nothing contained herein or otherwise shall
constitute an assumption by the Successor Trustee of any liability of the Resigning Trustee arising out of any breach by the Resigning Trustee in the performance or non-performance of the Resigning Trustee’s duties as Trustee, Registrar or
Paying Agent under the Indenture. 
 Section 405. This Instrument shall be governed by and construed in accordance
with the laws of the State of New York. 
 Section 406. This Instrument may be executed in any number of
counterparts each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. 

  
 5 

 Section 407. All notices will be deemed received when sent pursuant to the
following instructions: 
 TO THE SUCCESSOR TRUSTEE: 

Tina Vitale 
 Director of Corporate Trust 
 Computershare Trust Company, N.A.

 199 Water Street, 26th Floor 
 New York, NY 10038 
 Telephone: (212) 805-7345 

Facsimile: (212) 805-7388 
 with a copy to: 
 Harold L. Kaplan 

Mark F. Hebbeln 
 Foley & Lardner LLP 
 321 North Clark Street, Suite 2800

 Chicago, IL 60654-5313 

Telephone: (312) 832-4500 
 Facsimile: (312) 832-4700 
 TO THE RESIGNING TRUSTEE:

 Warren A. Goshine 
 Vice President 
 The Bank of Nova Scotia Trust Company of New York

 One Liberty Plaza 

23rd Floor 
 New York, NY 10006 
 Telephone: (212) 225-5279 

Facsimile: (212) 225-5436 
 TO THE ISSUER: 
 Eric J. Bock, Esq. 

Travelport LLC 
 300 Galleria Parkway 
 Atlanta, GA 30339 

Telephone: (212) 915-9160 
 Facsimile: (212) 915-9169 
 with a copy to: 

Andrea L. Nicolás 
 Skadden, Arps, Slate, Meagher & Flom LLP 
 Four Times
Square 
 New York, NY 10036 

Telephone: (212) 735-3416 
 Facsimile: (917) 777-3416 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have caused this Instrument of Resignation,
Appointment and Acceptance to be duly executed as of the day and year first above written. 
  

			
	TRAVELPORT LLC, as Issuer
		
	By	 	/s/ Rochelle J. Boas
		 	Name: Rochelle J. Boas
		 	Title: Authorized Person

  

			
	 COMPUTERSHARE TRUST COMPANY,
 N.A., as Successor Trustee

		
	By	 	/s/ Tina Vitale
		 	Name: Tina Vitale
		 	Title: Director, Corporate Trust

  

			
	THE BANK OF NOVA SCOTIA TRUST COMPANY OF NEW YORK, as Resigning Trustee
		
	By	 	/s/ Warren A. Goshine
		 	Name: Warren A. Goshine
		 	Title: Vice President

  
 7Amended and Restated Nerve Tissue Processing Agreement

 Exhibit 10.4.1 
 CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. §§ 200.80(B)(4) AND 230.406. THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND ARE MARKED ACCORDINGLY. THE CONFIDENTIAL PORTIONS
HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. 

AXOGEN 

AMENDED AND RESTATED NERVE TISSUE PROCESSING AGREEMENT 

 

			
	“LIFENET HEALTH”	 	“AXOGEN”
		
	LifeNet Health	 	AXOGEN CORPORATION
	1864 Concert Drive	 	13859 Progress Blvd
	Virginia Beach, VA 23453	 	Suite 100
		 	Alachua, FL 32615

 This Amended and Restated AXOGEN Nerve Tissue Processing Agreement (“Agreement”) consists of this
signature page, the attached Terms and Conditions, and the Exhibits marked below. This Agreement authorizes LIFENET HEALTH to process human cadaveric tissue for AXOGEN. The term of this Agreement shall commence on the Effective Date
and shall end as provided in the Terms and Conditions. For purposes of this Agreement, the “Effective Date” shall be the last date executed below. This Agreement becomes legally binding upon signature below by authorized representatives of
the parties, and supersedes the AXOGEN Nerve Tissue Processing Agreement by and between the parties, dated November 16, 2007 (the “Original Agreement”). 
 Exhibits 

                A — BATCH SCHEDULE 

                B — FEE SCHEDULE 

 

									
	LIFENET HEALTH	  		  	AXOGEN
					
	By:	  	 /s/ Gordon Berkstresser
	  	 	  	By:	  	 /s/ Jamie M. Grooms

					
	Title:	  	 CFO
	  	 	  	Title:	  	 CEO

					
	Date:	  	 2-26-08
	  	 	  	Date:	  	 2/27/08

 TERMS AND CONDITIONS 

 

	1.	PROCUREMENT 

 AXOGEN shall provide
LIFENET HEALTH with aseptically procured human allograft nerve tissue from its donor sources, suitable for Processing (as defined below) by LIFENET HEALTH into Product, and distribution by AXOGEN for clinical
implantation. The term “Product” means human nerve allografts based on AxoGen’s proprietary technology that meet Product Specifications (as defined below) and meet applicable federal, state and local regulations and in accordance with
the Standards for Tissue Banking of the AATB. The term “aseptic procurement” means the procurement of nerve tissues under aseptic conditions using aseptic techniques. 

 

	2.	SERVICES 

 LIFENET HEALTH shall
receive aseptically procured nerve tissues for processing in accordance with all applicable federal, state and local regulations and in accordance with the Standards for Tissue Banking of the AATB and, on a schedule agreed to in writing by the
parties, manage, perform and document aseptic debriding, processing and packaging of aseptically procured nerve tissues in accordance with AXOGEN’s proprietary process (“Process” or the act of “Processing”).
LifeNet Health will follow instructions and meet quality standards defined in AXOGEN created SOPs governing Processing and revised from time to time by AXOGEN and approved by LIFENET HEALTH on an ongoing basis and incorporated
herein and in accordance with all applicable federal, state and local regulations and in accordance with the Standards for Tissue Banking of the AATB (the “Product Specifications”). LIFENET HEALTH shall not make any changes to the
Process or Product Specifications without the prior written consent of AXOGEN. LIFENET HEALTH shall provide routine sterilization of daily supplies. LIFENET HEALTH reserves the right to refuse to Process any donor or donor
material that it, in its reasonable discretion, finds unacceptable. 
  

	3.	EQUIPMENT 

 AXOGEN shall supply
LIFENET HEALTH with all processing reagents and equipment (“Equipment”) necessary to Process each nerve tissue, excluding freezers, refrigerators, sealers (to be maintained by LIFENET HEALTH) and various disposable supplies
such as sterile gowns, sleeves, gloves, table covers, and various cleaning supplies, which shall be supplied by LIFENET HEALTH. AXOGEN shall own all the Equipment. LIFENET HEALTH shall assist AXOGEN in making any UCC or other
filings necessary to secure and evidence AXOGEN’s ownership of such Equipment as and when requested by AXOGEN. AXOGEN shall also supply the necessary calibration and preventative maintenance documents required for all
Equipment purchased for LIFENET HEALTH. LIFENET HEALTH will work with AXOGEN to perform the necessary Equipment calibrations and preventative maintenance. LIFENET HEALTH shall (i) use the Equipment only for
the purposes authorized by AXOGEN, (ii) restrict access to and use of the Equipment to those individuals for whom such access and use is required to conduct activities on behalf of AXOGEN and (iii) deliver the
Equipment to AXOGEN or its designee on the earlier of the termination or expiration of this Agreement, or as otherwise requested by AXOGEN. In the event that any item of Equipment under LIFENET HEALTH’s control
becomes damaged or rendered unusable due to negligence, LIFENET HEALTH shall replace or repair such Equipment at its own expense, with AXOGEN’S prior written approval.

	4.	DOCUMENTATION AND RECORD MAINTENANCE 

AXOGEN shall provide LIFENET HEALTH with documentation of the suitability of the nerve tissue donors. This documentation shall include a
copy of AXOGEN’S Medical Director release of donor nerve tissue, which shall include AXOGEN’S Medical Director confirmation of negative/nonreactive results of all required serologicals testing, acceptable pre-Processing
bacteriologic culture results of donor nerve tissue, acceptable results of any or all laboratory analyses and medical information, and acceptable review of donor consent form in accordance with local regulations. AXOGEN expressly warrants to
its knowledge the validity, accuracy and completeness of the information included in the documentation provided to LIFENET HEALTH. 

LIFENET HEALTH shall maintain appropriate records to document all aspects of Processing and training of LIFENET HEALTH employees, and
provide copies of such Processing records to AXOGEN. 
 LIFENET HEALTH shall also maintain adequate records to document
disposition of all materials received from AXOGEN, whether returned to AXOGEN or discarded. 
 AXOGEN is responsible for
the review of all documentation and the final release of nerve tissue grafts Processed for AXOGEN by LIFENET HEALTH. 
  

	5.	NOTICE OF UNSUITABILITY OR COMPLAINTS 

LIFENET HEALTH shall notify AXOGEN of problems with any nerve tissue provided for Processing, and consult with and follow instructions from
AXOGEN as to the disposition of such nerve tissue. AXOGEN and LIFENET HEALTH will immediately notify the other regarding any adverse events or complaints regarding Product. 
 AXOGEN shall have the right to reject any Product supplied that does not meet the Product Specifications (“Nonconforming Product”) by delivering written notice of such Nonconforming
Product within a reasonable time frame agreed by the parties. If such Nonconforming Product is (a) caused by the negligence or misconduct of LIFENET HEALTH or (b) failure of LIFENET HEALTH to follow AXOGEN’s
Processing standards or applicable laws, LIFENET HEALTH shall reduce proportionally the fee per batch; for example, if ten percent (10%) of the batch was determined to be Nonconforming Product, if as a result of either 5(a) or 5(b), the
fee per batch would be reduced by ten percent (10%). A batch is equal to one donor. 
  

	6.	MINIMUMS 

 AXOGEN shall provide a
minimum number of donors for Processing, and LIFENET HEALTH shall Process such minimum number of donors in each 12-month period beginning upon the effective date of the debridement processing arrangement between AXOGEN and LIFENET
HEALTH, in accordance with the batch schedule provided in Appendix A and as the same may be amended by the parties in writing from time to time. In the event LIFENET HEALTH receives less than the number of donors provided for in a given
period as contained in Appendix A, a minimum charge equal to the amount determined by subtracting the amount of donors provided from such minimum number of donors, multiplied by the fee in Appendix B, shall constitute the minimum fee due to
LIFENET HEALTH for such 

 

  

			
	 LIFENET HEALTH Initials and Date:      GB
2/26/08                
	  	AXOGEN Initials and Date:      JMG
2/27/08                

 
period. LIFENET HEALTH shall notify AXOGEN in writing 180 days in advance if it will not be able to 
 Process on the schedule agreed by the parties. In such case, the minimums for that 12-month period will not apply. 
  

	7.	SHIPPING 

 AXOGEN shall ship nerve
tissue to LIFENET HEALTH for Processing in the manner agreed to by the parties and in accordance with all applicable state, federal, local or transportation carrier rules and regulations. 

LIFENET HEALTH shall package all Product in a manner specified by AXOGEN in AXOGEN created SOPs governing packaging and revised from
time to time by AXOGEN and LIFENET HEALTH on an ongoing basis and incorporated herein and in accordance with all applicable federal, state and local regulations and in accordance with the Standards for Tissue Banking of the AATB.
LIFENET HEALTH shall return all Product to AXOGEN in a manner that complies with all transportation carrier, federal, state, and local regulations, and in a manner specified by AXOGEN in AXOGEN created SOPs governing
shipping and revised from time to time by AXOGEN and LIFENET HEALTH. 
 LIFENET HEALTH shall not be responsible for any
financial losses of AXOGEN for nerve tissue or Product that is lost, damaged or otherwise rendered useless in transit (to LIFENET HEALTH or from LIFENET HEALTH) except where such loss is due to the negligence or willful
misconduct of LIFENET HEALTH. 
  

	8.	BILLING 

AXOGEN shall pay all invoices for services rendered by LIFENET HEALTH within 30 days of the date on each invoice.
LIFENET HEALTH shall have the right to impose a charge of 1 1/2% per month on the undisputed unpaid balance of any past due amount owed by AXOGEN and the right to refuse to respond to future requests issued by AXOGEN until all such undisputed past due
amounts have been paid in full. 
  

	9.	FEES 

 AXOGEN shall pay for
Processing services in accordance with the fee schedule provided in Appendix B. 
 AXOGEN is responsible for all shipping fees to and
from LIFENET HEALTH and accordingly, shall provide LIFENET HEALTH with its transportation carrier account number. LIFENET HEALTH will direct transportation carrier to insure shipments of Product as specified by AXOGEN.

  

	10.	LIMITATIONS 

 LIFENET HEALTH does
not guarantee or warrant the performance of services under this Agreement except as provided in this Section 10 and Section 11. LIFENET HEALTH shall not be responsible for any loss or damage arising out of defective performance of
services unless attributable to LIFENET HEALTH’S negligence or willful misconduct. LIFENET HEALTH shall not be liable for any indirect, incidental, consequential or special damages resulting to AXOGEN from the operation of
this Agreement except in respect of a breach of Section 12 herein. 
 LIFENET HEALTH shall make its best efforts to maximize the
amount and/or type of nerve tissue grafts that can or will be used for Processing from a single nerve tissue donor based on AXOGEN Specifications. Except as defined in this Agreement in regards to the stipulations of Nonconforming Product in
Section 5, LIFENET HEALTH shall not be liable or responsible to AXOGEN, its customers, or patients for being unable to perform any services in the

 
manner requested or at the time specified, but shall use its best efforts to achieve complete services in the time requested by AXOGEN. 

 

	11.	STANDARDS 

 LIFENET HEALTH and
AXOGEN will comply with all applicable standards of procedure and operation required by the AATB and all applicable federal and state regulatory requirements throughout the term of this Agreement. LIFENET HEALTH will update its federal
and state registrations/licenses to include the processing of nerve tissue. The warranties in Section 10 and Section 11 are LIFENET HEALTH’S only warranties with respect to the provision of Processing services and Product, and
they are exclusive and in lieu of all other warranties whether oral or written. 
  

	12.	CONFIDENTIAL INFORMATION 

 Neither party
(“Receiving Party”) shall use in any way other than as required for the proper performance of its obligations under this Agreement and shall not disclose to any third party any information given to it by the other party (“Disclosing
Party”) or otherwise acquired by a Receiving Party relating to the Disclosing Party’s nerve tissue grafts, processes (and in the case of AXOGEN as the Disclosing Party, including but not limited to the Process), plans, records,
techniques, procedures, customers, trade secrets or general business operations. Any information that a Receiving Party legally possessed prior to disclosure to it by the Disclosing Party’s representative, which is lawfully published or which
otherwise lawfully becomes a part of general knowledge from sources other than Receiving Party shall not be subject to the restrictions of this Section 12. The obligations under this Section 12 shall survive any expiration or termination
of this Agreement. In addition to the forgoing terms of this Section 12, all information disclosed by the Disclosing Party to the Receiving Party in advance of the Effective Date pursuant to the Confidentiality Agreement (the “CDA”)
by and between AXOGEN and LIFENET HEALTH, dated September 20, 2007, or the Original Agreement is hereby subject to this Agreement, including, without limitation, this Section 12. All information generated by LIFENET
HEALTH in performing the services hereunder or related to the Process shall be the information of AXOGEN subject to the confidentiality and nonuse obligations herein. 

 

	13.	INTELLECTUAL PROPERTY 

 LIFENET HEALTH
acknowledges and agrees that AXOGEN’S Process and all methods, practices and works related thereto, whether or not patentable, and any applicable patents relating thereto or arising therefrom, are intellectual property owned solely
by AXOGEN (“AXOGEN Intellectual Property”). In the event that during the term of this AGREEMENT, an employee(s), or contract worker(s) of LIFENET HEALTH alone conceives of an improvement, invention or discovery solely
relating to LIFENET HEALTH proprietary technology, such improvement, invention, or discovery, and any corresponding proprietary rights throughout the world (“LIFENET Technology”), shall be the property of LIFENET
HEALTH. AXOGEN shall have a royalty free, non-exclusive right to practice and use any such LIFENET HEALTH Technology as it pertains to Processing whether or not covered by any claim of any patent that may issue under the terms of
this Article VII. In the event that during the term of this AGREEMENT, an employee(s), and/or contract worker(s) of LIFENET HEALTH or AXOGEN or both jointly conceive of an improvement, invention or discovery, and any corresponding
proprietary rights throughout the world, other than LIFENET HEALTH Technology (a) relating to AXOGEN Intellectual Property or (b) during the performance of the services hereunder (“AXOGEN Technology”), such
AXOGEN Technology shall be the property of AXOGEN. LIFENET HEALTH shall have no right to use the AXOGEN Intellectual Property and AXOGEN Technology except in its performance of this Agreement. LIFENET HEALTH shall,
and shall cause LIFENET HEALTH personnel to, keep appropriate records of the work done pursuant to this Agreement, including

 

  

			
	 LIFENET HEALTH Initials and Date:      GB
2/26/08                
	  	AXOGEN Initials and Date:      JMG
2/27/08                

 
laboratory notebooks or batch records, sufficient to properly document the results of such work and otherwise sufficient to determine identity and dates of inventorship of any new AXOGEN
Intellectual Property or AXOGEN Technology; and shall make such records available to AXOGEN upon reasonable notice during LIFENET HEALTH normal business hours. 

 

	14.	PUBLICATION 

 No announcement, news
release, public statement, publication, or presentation relating to the existence of this Agreement, the subject matter herein, or either party’s performance hereunder (collectively, a “Publication”) will be made by a party without
the other party’s prior written approval whether during or after the termination of this Agreement, except as required by law. Each party agrees to submit each Publication it proposes to make to the other party for purposes of such other
party’s review, comment and approval. Each party further agrees to respond as promptly as reasonably practicable and likewise agrees that it will not unreasonably withhold approval of such Publication. The parties agree that they will use
reasonable efforts to coordinate the initial announcement or press release relating to the existence of this Agreement so that such initial announcement or press release by each is made contemporaneously. 

 

	15.	INDEMNIFICATION 

 AXOGEN shall
indemnify and hold harmless LIFENET HEALTH, its agents, its officers, trustees and employees from and against all third party claims, damages, suits, liabilities, costs, charges, demands, losses and other expenses (including, but not limited
to, attorneys’ fees) attributable to bodily injury, sickness, disease or death or to injury or destruction of tangible property (“Losses”) arising out of or resulting in whole or in part from any act or omission of AXOGEN, its
employees or any other party acting under AXOGEN’S supervision or control, provided, however, that the foregoing indemnification obligations shall not apply to the extent that such Losses are caused by action or omission to act of
LIFENET HEALTH for which LIFENET HEALTH is required to indemnify AXOGEN under the paragraph below. 
 LIFENET HEALTH
shall indemnify and hold harmless AXOGEN, its agents, its officers, trustees and employees from and against all Losses arising out of LIFENET HEALTH’S failure to perform in accordance with its obligations under the terms of this
Agreement or the negligence or willful misconduct of LIFENET HEALTH. 
  

	16.	LIABILITY INSURANCE 

 Each party shall
each maintain in force during the term of this Agreement professional liability insurance coverage under a policy or policies issued by a carrier satisfactory to the other party with minimum limits of five million United States dollars ($5,000,000
U.S.), and no more than a fifty thousand United State dollars ($50,000 U.S.) deductible. Each party shall provide the other with a certificate(s) of insurance suitable to the other party which state that the above required coverage is in full force
and effect and will remain in effect throughout the term of this Agreement unless the carrier provides not less than sixty (60) days prior written notice of expiration or cancellation to both the insured party and the party to whom such
certificate is issued. 
  

	17.	FORCE MAJEURE 

 Performance under this
Agreement may be delayed by a party, and the other party shall not be held in breach of any of its obligations under this Agreement or be liable for damages resulting from such delay if such delay is due to acts of God, acts of civil or
military authority, fires, floods, labor troubles, unavailability of transportation, epidemics, war or riot.

	18.	TERM AND TERMINATION 

 This Agreement
shall be effective as of the Effective Date and shall remain in effect for twenty-four (24) months. Following the initial term of twenty-four (24) months, this Agreement shall automatically renew for additional terms of one (1) year
unless written notice of termination is received by one party from the other party at least one hundred eighty (180) days prior to any such automatic renewal. 
 Either party may terminate this Agreement, in the event the other party has committed a material breach by giving the alleged breaching party 60 days to cure the breach. This Agreement is subject to
immediate termination for failure to maintain the required insurance coverage under Section 15 or for becoming insolvent or filing bankruptcy. 
 Termination shall not release or affect, and this Agreement shall remain fully operative as to, any obligations or liabilities incurred by AXOGEN prior to the effective date of such termination;
provided that all indebtedness of AXOGEN to LIFENET HEALTH of any kind shall become immediately due and payable on the effective date of termination, and LIFENET HEALTH may deduct from any sums its owes to AXOGEN any sums
owed by AXOGEN to LIFENET HEALTH. 
 Termination of this Agreement shall not terminate any provision of this Agreement intended to
survive termination, including but not limited to Sections 10 and 12. 
  

	19.	MISCELLANEOUS 

  

	A.	This Agreement and the Appendices attached hereto constitute the entire agreement between the parties and supersedes any and all other oral or written agreements or
understandings regarding this arrangement, including, without limitation, the Original Agreement. This Agreement may not be amended except by a written document signed by both parties. 

 

	B.	All notices required or desired to be given under this Agreement shall be deemed delivered when deposited in U.S. Certified Mail, return receipt requested, postage
prepaid, addressed to the recipient at the address indicated in the signature page of this Agreement or at such other address as the recipient may hereafter provide to the other party hereto. Any such notice shall be deemed to be delivered two
(2) days after such notification is deposited in the U.S. Mail, certified, postage prepaid, or upon the hand delivery of such notice, as the case may be. 

 

	C.	Each party shall, as and when required by the other party, do all acts and execute all documents as may be reasonably necessary to give effect to the provisions of this
Agreement. 

  

	D.	This Agreement and the performance of any services hereunder shall be governed by and construed in accordance with the laws of the State of Delaware excluding its
conflict of laws provisions. 

  

	E.	Neither Party shall assign nor transfer this Agreement or any interest, right or obligation hereunder without the prior written consent of the other party, which
consent shall not be unreasonably withheld. 

  

	F.	All agreements and covenants of this Agreement are severable, and if any are declared invalid by a competent court, this Agreement shall be interpreted as if the
invalid agreement or covenant were not contained in this Agreement, and all remaining covenants and provisions of this Agreement shall remain in full force and effect. 

 

	G.	Neither party shall be deemed the drafter of this Agreement and the interpretation of any ambiguity construed in this Agreement will not be affected by claims that a
particular party drafted any portion hereof. 

  

	H.	The waiver of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach by any party. 

END OF TERMS AND CONDITIONS

 

  

			
	 LIFENET HEALTH Initials and Date:      GB
2/26/08                
	  	AXOGEN Initials and Date:      JMG
2/27/08                

 APPENDIX A 
 BATCH SCHEDULE 
 [**] 

 

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request. 

  

			
	 LIFENET HEALTH Initials and Date:      GB
2/26/08                
	  	AXOGEN Initials and Date:      JMG
2/27/08                

 APPENDIX B 
 FEE SCHEDULE 
  

	1)	The fee for providing services to Process nerve tissue into Product according to AXOGEN Specifications, but not including [**], will be determined on [**].

  

	 	Upon successful implementation of a revised AXOGEN SOP for a process improvement that materially reduces [**], the base fee will be reduced [**].

  

	 	Any process changes involving material changes in technical methods, supplies, equipment or product quality requirements will be subject to mutually agreed upon
incremental adjustments. 

  

	2)	[**]. 

  

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request. 

  

			
	 LIFENET HEALTH Initials and Date:      GB
2/26/08                
	  	AXOGEN Initials and Date:      JMG
2/27/08                

 APPENDIX C 
 CONFIDENTIALITY AGREEMENT 
 [See Attached] 

  

			
	 LIFENET HEALTH Initials and Date:      GB
2/26/08                
	  	AXOGEN Initials and Date:      JMG
2/27/08                

 AXOGEN, INC 
 CONFIDENTIALITY AGREEMENT 
 This Agreement is made this 20th day of September, 2007
(“Effective Date”) by and between Axogen, Inc. with an address at 13859 Progress Blvd., Ste. 100, Alachua, FL 32615 (“the Company”) and LifeNet Health (“LifeNet”), with an address at 1864 Concert Drive, Virginia
Beach, VA 23453. 
 Whereas, the Company and LifeNet wish to discuss together a possible business relationship involving the
Company and LifeNet where LifeNet recovers tissue from qualified donors for the Company and where LifeNet provides space and/or personnel to process tissue for the Company according to Company’s propriety process. 

Whereas, this may involve the exchange of confidential information from one party to the other, the parties agree that their confidential
information shall be disclosed using the following terms and conditions: 
 1. Definition. For the purposes of this
Agreement, the term “Confidential Information” shall mean without limitation, ideas, concepts, plans, designs, marketing techniques, sales techniques, forecasts, products, technology, methods, procedures, pricing, costs, cost reports,
customer prospects, designs, computer systems, passwords, computer software, procedures, methods, formulae, financial statements, assets, liabilities, revenues, business methods, marketing information, marketing methods, acquisition plans, contract
terms, contract negotiations, compensation information, structures and plans, employee responsibilities and duties, copyright, trademark and patent applications, all business and technical information, data, know-how, costs, projections, samples,
revenue projections, business plans, clinical protocols, formulae or other information which are owned or are in the possession of one or more of the parties to this Agreement, disclosed by one or more of the parties to the other, directly or
indirectly, in writing or orally. 
 2. Non-Disclosure of Confidential Information. This Agreement will apply to all
Confidential Information disclosed from one party (the “Disclosing Party”) to the other (the “Recipient”), as of the Effective Date of this Agreement as set forth above. Each party agrees not to use the Information received for
any purpose other than the Discussion Purpose. The Recipient shall limit disclosure of the Confidential Information to its employees, officers, directors, affiliates and consultants with a bona fide need to know, but only to the extent
necessary to carry out the Discussion Purpose. All such individuals previously shall have entered into a Confidentiality Agreement with the Recipient or otherwise be bound under terms at least as restrictive as those contained herein. The Recipient
of the Confidential Information shall hold it in strict confidence and shall take all reasonable efforts to prevent disclosure of such Information to persons outside of its own organization and unauthorized use for a period of seven (7) years,
except, the Recipient shall not be liable for use or for disclosure to others of Information that: 
 (a) is or subsequently
becomes part of the public domain through no fault of the Recipient of the Information; 

  
 -8-

 (b) is received from a third party under no obligation of confidentiality to the Disclosing
Party and who has a lawful right to disclose the Information; 
 (c) was known by the Recipient prior to the time of first
disclosure by the Disclosing Party, as demonstrated by written documentation; 
 (d) is independently developed by the Recipient
without the aid, application or use of such Confidential Information, as demonstrated by written documentation; 
 (e) is
required to be disclosed by law, or pursuant to the direction of a court or government agency, provided the Recipient provides the Disclosing Party with prior written notice of the requirement and permits discussion between the parties with the
objective of lawfully limiting the Confidential Information required to be disclosed. 
 3. Return of Materials. Any
materials or documents of one party which are furnished to the other party will be promptly returned to the Disclosing Party, accompanied by all copies of such documentation made by the Recipient, at the Disclosing Party’s request, except that
one copy of any written information may be retained by the Receiving Party in legal archives. 
 4. Miscellaneous.
(i) This Agreement is binding upon and for the benefit of the parties, and the right to the Confidential Information granted to the Recipient may not be assigned; (ii) This Agreement shall not be construed to grant any license or other
rights except as specified herein; (iii) Each Disclosing Party warrants that it believes that (a) it is the owner or licensee of its Confidential Information or otherwise has the right to disclose such Confidential Information in its
possession and (b) it has the right to enter into the Agreement without any breach of its obligations to others; (iv) Each Disclosing Party makes no other warranty relating to the Confidential Information and the use to be made thereof by
the Recipient and disclaims all implied warranties; (v) The parties agree that the disclosure of Confidential Information by a Recipient without the Disclosing Party’s written permission may cause the Disclosing Party irreparable harm and
that any breach of this Agreement may entitle a party injunctive relief, in addition to any other legal remedies available to it, in any court of competent jurisdiction; (vi) This document may be executed in counterparts and delivered by
facsimile transmission; (vii) Any amendment to this Agreement shall be in writing and signed by an authorized representative of the parties; (viii) Any dispute arising under this Agreement shall be governed by the laws of the State of
Florida; (ix) This agreement shall have a seven (7) year term beginning on the Effective Date. Those provisions of this Agreement that, by their language, are intended to survive termination of this Agreement shall so survive. 

 

			
	 NAME
	  	AXOGEN, INC.
		
	By: /s/ Bud Brame	  	By: /s/ John P. Engles
		
	Print Name: Bud Brame	  	Print Name: John P. Engles 
		
	Title: VP of Tissue Operations	  	Title: Vice President

  
 -9-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]